Opko Health Company Profile (NASDAQ:OPK)

Opko Health trades on the NASDAQ under the ticker symbol "OPK."

Opko Health, Inc. (NASDAQ:OPK) announced its earnings results on Tuesday, August, 8th. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The business had revenue of $314.20 million for the quarter, compared to analysts' expectations of $322.64 million. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The firm's revenue was down 12.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.02 earnings per share. View Opko Health's Earnings History.

Opko Health is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Opko Health.

9 analysts have issued 1 year price objectives for Opko Health's shares. Their forecasts range from $6.50 to $25.00. On average, they anticipate Opko Health's stock price to reach $15.25 in the next twelve months. View Analyst Ratings for Opko Health.

Here are some recent quotes from research analysts about Opko Health stock:

• 1. Cantor Fitzgerald analysts commented, "Expect Rayaldee sales to pick up the pace. Sales force expansion for Rayaldee is under way, and OPK has made substantial progress in obtaining formulary access for Rayaldee. With more-extensive insurance coverage, OPK is continuing to expand its field-based sales force to 70 representatives from the original 35. Also, on 6/22/17, OPK announced that the Kidney Disease Improving Global Outcomes (KDIGO) organization had updated its Clinical Practice Guidelines for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)." (8/17/2017)
• 2. According to Zacks Investment Research, "OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. " (8/12/2017)
• 3. Jefferies Group LLC analysts commented, "4Q16 revenues came in well below expectations (-11% vs. consensus). With Rayaldee off to a slow start & no visibility into the timing of reimbursement from Novitas for 4Kscore (two of OPK's only/most important new growth drivers), we see few NT catalysts for the stock & further downside risk to consensus forecasts. Expect shares to open lower on the 4Q rev miss & recalibrated NT expectations for Rayaldee & 4Kscore. PT to $8 (from $10)." (3/2/2017)

Opko Health saw a increase in short interest in August. As of August 31st, there was short interest totalling 77,815,315 shares, an increase of 2.1% from the August 15th total of 76,186,977 shares. Based on an average daily volume of 3,869,284 shares, the days-to-cover ratio is currently 20.1 days. Currently, 23.3% of the company's shares are sold short.

Some companies that are related to Opko Health include Dr. Reddy's Laboratories Ltd (RDY), Catalent (CTLT), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Taro Pharmaceutical Industries (TARO), Akorn (AKRX), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Horizon Pharma PLC (HZNP), Theravance Biopharma (TBPH), Cambrex Corporation (CBM), Akcea Therapeutics (AKCA), Impax Laboratories (IPXL), Emergent Biosolutions (EBS), Innoviva (INVA) and Pacira Pharmaceuticals (PCRX).

Opko Health's management team includes the folowing people:

• Phillip Frost M.D., Chairman of the Board, Chief Executive Officer
• Jane H. Hsiao Ph.D., Vice Chairman of the Board, Chief Technical Officer
• Adam E. Logal, Chief Financial Officer, Senior Vice President
• Steven D. Rubin Esq. J.D., Executive Vice President - Administration, Director
• Akhtar Ashfaq M.D., Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division
• Thomas Nusbickel, Chief Commercial Officer of the Company's Renal Division
• Richard M. Krasno Ph.D., Independent Director
• Richard Alan Lerner M.D., Independent Director
• John A. Paganelli, Independent Director
• Richard C. Pfenniger Jr., Independent Director

Opko Health's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.76%), BlackRock Inc. (4.09%), State Street Corp (2.03%), FMR LLC (0.97%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.57%) and Dimensional Fund Advisors LP (0.32%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard A Lerner and Steven D Rubin. View Institutional Ownership Trends for Opko Health.

Opko Health's stock was sold by a variety of institutional investors in the last quarter, including Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Menora Mivtachim Holdings LTD., Harel Insurance Investments & Financial Services Ltd., FMR LLC, Wells Fargo & Company MN, Scott & Selber Inc., IFP Advisors Inc and Virtu KCG Holdings LLC. View Insider Buying and Selling for Opko Health.

Opko Health's stock was purchased by a variety of institutional investors in the last quarter, including Alps Advisors Inc., State Street Corp, Jaffetilchin Investment Partners LLC, Vanguard Group Inc., Stevens Capital Management LP, BlackRock Inc., Cornerstone Capital Management Holdings LLC. and Schwab Charles Investment Management Inc.. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard A Lerner and Steven D Rubin. View Insider Buying and Selling for Opko Health.

Shares of Opko Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Opko Health stock can currently be purchased for approximately $6.71.